title: Deriving Biomonitoring Equivalents for selected E- and P-series glycol ethers for public health risk assessment.
abstract: Glycol ethers are a widely used class of solvents that may lead to both workplace and general population exposures. Biomonitoring studies are available that have quantified glycol ethers or their metabolites in blood and/or urine amongst exposed populations. These biomonitoring levels indicate exposures to the glycol ethers, but do not by themselves indicate a health hazard risk. Biomonitoring Equivalents (BEs) have been created to provide the ability to interpret human biomonitoring data in a public health risk context. The BE is defined as the concentration of a chemical or metabolite in a biological fluid (blood or urine) that is consistent with exposures at a regulatory derived safe exposure limit, such as a tolerable daily intake (TDI). In this exercise, we derived BEs for general population exposures for selected E- and P-series glycol ethers based on their respective derived no effect levels (DNELs). Selected DNELs have been derived as part of respective Registration, Evaluation, Authorisation and Regulation of Chemicals (REACh) regulation dossiers in the EU. The BEs derived here are unique in the sense that they are the first BEs derived for urinary excretion of compounds following inhalation exposures. The urinary mass excretion fractions (Fue) of the acetic acid metabolites for the E-series GEs range from approximately 0.2 to 0.7. The Fues for the excretion of the parent P-series GEs range from approximately 0.1 to 0.2, with the exception of propylene glycol methyl ether and its acetate (Fue = 0.004). Despite the narrow range of Fues, the BEs exhibit a larger range, resulting from the larger range in DNELs across GEs. The BEs derived here can be used to interpret human biomonitoring data for inhalation exposures to GEs amongst the general population.
authors.affiliation: Summit Toxicology, Richland, WA, United States.
authors.forename: Torka
authors.initials: T
authors.lastname: Poet
authors.affiliation: Toxicology and Environmental Research and Consulting, The Dow Chemical Company, United States.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Ball
authors.affiliation: Summit Toxicology, Allenspark, CO, United States. Electronic address: shays@summittoxicology.com.
authors.forename: Sean M
authors.initials: SM
authors.lastname: Hays
mesh_terms: D004781:Environmental Exposure / Q000032:analysis*; D004784:Environmental Monitoring / Q000379:methods*; D004785:Environmental Pollutants / Q000097:blood / Q000378:metabolism* / Q000652:urine; D004987:Ethers / Q000097:blood / Q000378:metabolism* / Q000652:urine; D006018:Glycols / Q000097:blood / Q000378:metabolism* / Q000652:urine; D015386:Hazardous Substances / Q000097:blood / Q000378:metabolism* / Q000652:urine; D006801:Humans; D019055:No-Observed-Adverse-Effect Level; D011634:Public Health; D012016:Reference Values; D012997:Solvents
chemical_list: D004785:Environmental Pollutants; D004987:Ethers; D006018:Glycols; D015386:Hazardous Substances; D012997:Solvents
keywords: Biomonitoring; Biomonitoring Equivalents; Exposure assessment; PBPK; Risk assessment